BRISTOL-MYERS SQUIBB - LONG-TERM FOLLOW-UP DATA FROM PHASE 3 STUDY OF CAMZYOS® (MAVACAMTEN) UNDERSCORES ESTABLISHED EFFICACY AND SAFETY PROFILE IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)

Reuters · 09/01 07:33
BRISTOL-MYERS SQUIBB - LONG-TERM FOLLOW-UP DATA FROM PHASE 3 STUDY OF CAMZYOS® (MAVACAMTEN) UNDERSCORES ESTABLISHED EFFICACY AND SAFETY PROFILE IN PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)